Xu, Qiaobing et al. published their patent in 2022 |CAS: 1949837-12-0

The Article related to cancer antitumor lipid nanoparticle protac protein degradation, Pharmaceuticals: Pharmaceutics and other aspects.COA of Formula: C49H60ClN9O7S2

On May 5, 2022, Xu, Qiaobing; Chen, Jinjin published a patent.COA of Formula: C49H60ClN9O7S2 The title of the patent was Enhanced hydrophobic tag-induced protein degradation using lipid nanoparticle delivery. And the patent contained the following:

Disclosed are conjugates, comprising a PROTAC and a protein. Also disclosed are nanoparticles, comprising the conjugates disclosed herein and a membrane. The present disclosure further relates to therapeutic methods of using the conjugates and nanoparticles. The experimental process involved the reaction of (2S,4R)-1-((2S)-2-(tert-butyl)-15-((6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-4,14-dioxo-6,10-dioxa-3,13-diazapentadecan-1-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide(cas: 1949837-12-0).COA of Formula: C49H60ClN9O7S2

The Article related to cancer antitumor lipid nanoparticle protac protein degradation, Pharmaceuticals: Pharmaceutics and other aspects.COA of Formula: C49H60ClN9O7S2

Referemce:
1,2,3-Triazole – Wikipedia,
Triazoles – an overview | ScienceDirect Topics